Clinical Trials · NCT05749289
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
- Phase
- Phase 2/Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrollment
- 400
- Start date
- Dec 2022
- Locations
- 1 site, China
- Primary endpoint
- Diagnostic value